These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26897014)

  • 1. Neuro-oncology biotech industry progress report.
    Chakraborty S; Bodhinayake I; Chiluwal A; Langer DJ; Ruggieri R; Symons M; Boockvar JA
    J Neurooncol; 2016 May; 128(1):175-182. PubMed ID: 26897014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry progress report on neuro-oncology: Biotech update 2013.
    Ottenhausen M; Bodhinayake I; Banu M; Kesavabhotla K; Ray A; Boockvar JA
    J Neurooncol; 2013 Nov; 115(2):311-6. PubMed ID: 23949146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Industry progress report on neuro-oncology: a biotech update.
    Haber JS; Banu MA; Ray A; Kesavabhotla K; Boockvar JA
    J Neurooncol; 2013 Apr; 112(2):315-21. PubMed ID: 23423513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on glioma biotechnology.
    Abrams M; Reichman N; Khatri D; Patel NV; D'Amico RS; Wong T; Fralin S; Li M; Symons M; Langer D; Filippi CG; Boockvar JA
    Clin Neurol Neurosurg; 2020 Aug; 195():106075. PubMed ID: 32653731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrastructure, biotech top African science summit agenda.
    Scott C
    Nat Med; 2007 Mar; 13(3):228. PubMed ID: 17342102
    [No Abstract]   [Full Text] [Related]  

  • 8. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
    Gruber AC
    Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Business Ethics 101 for the biotech industry.
    MacDonald C
    BioDrugs; 2004; 18(2):71-7. PubMed ID: 15046523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
    Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotech pharmaceuticals and biotherapy: an overview.
    Steinberg FM; Raso J
    J Pharm Pharm Sci; 1998; 1(2):48-59. PubMed ID: 10945918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [NEURO-ONCOLOGY A NEW FIELD IN DAVIDOFF CANCER CENTER AT RABIN MEDICAL CENTER].
    Yust-Katz S; Limon D; Abu-Shkara R; Siegal T
    Harefuah; 2017 Aug; 156(8):512-516. PubMed ID: 28853528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan Biotech Forum: London 2010.
    Al-Shamahi A
    IDrugs; 2010 Nov; 13(11):756-8. PubMed ID: 21046519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fourth Bioelectronic Medicine Summit "Technology Targeting Molecular Mechanisms": current progress, challenges, and charting the future.
    Datta-Chaudhuri T; Zanos T; Chang EH; Olofsson PS; Bickel S; Bouton C; Grande D; Rieth L; Aranow C; Bloom O; Mehta AD; Civillico G; Stevens MM; Głowacki E; Bettinger C; Schüettler M; Puleo C; Rennaker R; Mohanta S; Carnevale D; Conde SV; Bonaz B; Chernoff D; Kapa S; Berggren M; Ludwig K; Zanos S; Miller L; Weber D; Yoshor D; Steinman L; Chavan SS; Pavlov VA; Al-Abed Y; Tracey KJ
    Bioelectron Med; 2021 May; 7(1):7. PubMed ID: 34024277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BioAsia Licensing and Deal-Making Summit-SRI Conference. Life science partnering and investment on the Pacific Rim 2-3 August, 2004, Coronado, CA, USA.
    Xu J
    IDrugs; 2004 Sep; 7(9):841-5. PubMed ID: 15470601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines and policies for medical writers in the biotech industry: an update on the controversy.
    Foote M
    Biotechnol Annu Rev; 2004; 10():259-64. PubMed ID: 15504710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotech research: bringing better therapies to the people.
    Heinzelmann E
    Chimia (Aarau); 2010; 64(1-2):91-3. PubMed ID: 21137693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourth Medical Biotech Forum of the Chinese Medical Biotech Association. 8-10 August 2009, Dalian, China.
    Felzmann T
    IDrugs; 2009 Oct; 12(10):629-32. PubMed ID: 19790012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.